A case of refractory Mooren's ulcer successfully treated with systemic immunosuppressive therapy

Erika Yumori-Matsunaka1, Kaoru Araki-Sasaki1, Atsuko Ishimoto1

  • 1Department of Ophthalmology, Kansai Medical University, Hirakata, Osaka, Japan.

Immunological Medicine
|March 26, 2026
PubMed

We will report the efficacy and precautions for the systemic administration of immunosuppressants in refractory Mooren's ulcer. A 65-year-old woman with refractory Mooren's ulcer was referred to our hospital. Initial visual acuity was 0.01 (logMAR 2.0) in the right eye and hand motion vision in the left eye. The right eye showed anterior chamber hemorrhage and a circumscribed peripheral ulcer with corneal perforation. The patient underwent conjunctival excision and lamellar keratoplasty in the right eye. Systemic methylprednisolone and oral cyclosporine (CsA) were initiated, along with topical betamethasone and tacrolimus. Systemic medications were continued with gradual tapering. At 8.5 months, the patient developed varicella-zoster virus (VZV)-associated keratouveitis in the right eye. Systemic steroid administration was promptly discontinued, but CsA was continued at a reduced dose. Antiviral treatment led to prompt improvement. Oral CsA was discontinued after 16 months of treatment. The total cumulative dose of PSL was 1,803 mg, and CsA was 64,730 mg. No relapses occurred during 36 months of follow-up. Multidisciplinary care was required to manage systemic complications. The long-term systemic administration of steroids and immunosuppressants may be associated with sustained remission in a patient with refractory Mooren's ulcer with appropriate monitoring for various systemic conditions caused by immunosuppression.

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
628
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
920
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
608
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
616